A. Gazit

发表

Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor.

J. Kuriyan, F. Sicheri, A. Levitzki, 1999, Molecular cell.

Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase.

Y. Pommier, Jessie Yung, A. Levitzki, 1995, Biochemistry.

Alpha-cyanocinnamide derivatives: a new family of non-peptide, non-sulfhydryl inhibitors of Ras farnesylation.

A. Levitzki, A. Gazit, E. Poradosu, 1999, Bioorganic & medicinal chemistry.

Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors

N. Shenoy, A. Levitzki, A. Gazit, 1999, The British journal of dermatology.

Disruption of microtubules in living cells by tyrphostin AG-1714.

B. Geiger, A. Bershadsky, A. Levitzki, 2000, Cell motility and the cytoskeleton.

Suppression of Experimental Autoimmune Encephalomyelitis by Tyrphostin AG-556

A. Levitzki, A. Gazit, D. Soffer, 1998, Experimental Neurology.

The Tyr-Kinase Inhibitor AG879, that Blocks the ETK-PAK1 Interaction, Suppresses the RAS-induced PAK1 Activation and Malignant Transformation

J. Baell, Y. Yamashita, H. Mano, 2004, Cancer biology & therapy.

Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.

G. Mcmahon, P. Hirth, A. Levitzki, 1998, The Journal of pharmacology and experimental therapeutics.

The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers

A. Levitzki, A. Gazit, C. Gilon, 1991, The Journal of cell biology.

Crosslinking of nucleic acids and proteins by bisulfite.

A. Gazit, R. Shapiro, 1977, Advances in experimental medicine and biology.

Distinct roles of the receptor tyrosine kinases c-ErbB and c-Kit in regulating the balance between erythroid cell proliferation and differentiation.

H. Beug, A. Levitzki, M. Hayman, 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

The cytoskeleton‐associated TCR ζ chain is constitutively phosphorylated in the absence of an active p56lck form

S. Caplan, A. Gazit, A. Ezernitchi, 2001, European journal of immunology.

The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor.

A. Levitzki, A. Saltiel, A. Gazit, 1993, Biochemistry.

Platelet‐derived growth factor isoforms prevent cell death during starvation of AKR‐2B fibroblasts

A. Gazit, A. Simm, V. Hoppe, 1994, Journal of cellular physiology.

Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives.

A. Levitzki, E. Ségal-Bendirdjian, A. Jacquemin-Sablon, 1994, Biochemical pharmacology.

Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation.

G. Mills, A. Levitzki, A. Gazit, 1991, The Journal of clinical investigation.

Inhibition of protein-tyrosine kinases by tyrphostins.

A. Levitzki, A. Gazit, C. Gilon, 1991, Methods in enzymology.

Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis

A. Gazit, E. Priel, S. Slavin, 2012, EMBO molecular medicine.

Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas

A. Levitzki, A. Gazit, B. Klein, 2002, Journal of Pharmacology and Experimental Therapeutics.

Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes.

A. Levitzki, A. Gazit, B. Klein, 1999, The Journal of pharmacology and experimental therapeutics.

Substrate competitive inhibitors of IGF-1 receptor kinase.

A. Levitzki, A. Gazit, G. Blum, 2000, Biochemistry.

Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity.

A. Levitzki, A. Gazit, A. Novogrodsky, 1996, The Journal of infectious diseases.

Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.

S. Colla, A. Levitzki, A. Gazit, 1999, Blood.

Inhibition of platelet activation by tyrosine kinase inhibitors.

A. Levitzki, A. Gazit, C. Gilon, 1992, Biochemical pharmacology.

Screening of peptidomimetic tyrosine kinase inhibitors for inducing programmed cell death

G. Kéri, B. Szende, Z. Szegedi, 1999 .

The effect of early and late treatment with the tyrphostin AG-556 on the progression of experimental autoimmune myocarditis.

I. Barshack, A. Levitzki, A. Gazit, 2004, Experimental and molecular pathology.

Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296.

C. Heldin, A. Levitzki, A. Gazit, 1997, Biochemistry.

Tyrphostins inhibit the epidermal growth factor receptor‐mediated breakdown of phosphoinositides

A. Levitzki, A. Gazit, C. Gilon, 1989, FEBS letters.

Synthesis and receptor-binding affinity of fluorotamoxifen, a possible estrogen-receptor imaging agent.

A. Gazit, J. Shani, S. Biran, 1985, Journal of medicinal chemistry.

Tyrphostin induces non‐apoptotic programmed cell death in colon tumor cells

G. Kéri, I. Benedeczky, B. Szende, 1995, Cell biology international.

Differential Activation of Mitogen-activated Protein Kinase and S6 Kinase Signaling Pathways by 12-O-Tetradecanoylphorbol-13-acetate (TPA) and Insulin

A. Gazit, R. Seger, Y. Zick, 1995, The Journal of Biological Chemistry.

Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins.

A. Levitzki, Y. Ben-Neriah, A. Gazit, 1992, The Journal of biological chemistry.

Telomerase activity and expression in adult human mesenchymal stem cells derived from amyotrophic lateral sclerosis individuals.

A. Gazit, E. Priel, S. Slavin, 2009, Cytotherapy.

Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action.

S. Segal, A. Gazit, E. Priel, 1994, Cancer research.

Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation.

A. Zilberstein, J. Schlessinger, A. Levitzki, 1989, The Journal of biological chemistry.

Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins.

G. Mcmahon, A. Levitzki, A. Gazit, 1996, Journal of medicinal chemistry.

Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.

C. Heldin, A. Levitzki, A. Gazit, 1994, Cancer research.

Benzannelated [9] and [13] annulenes: Formation, structural properties and the effect of benzannelation on the aromaticity of the (4n+2) π anionic sy

I. Willner, A. Gazit, M. Rabinovitz, 1979 .

Two allyl-isomeric dibenzocyclononatetraenes

A. Gazit, M. Rabinovitz, E. Bergmann, 1970 .

Tyrosine kinase inhibition: an approach to drug development.

A. Levitzki, A. Gazit, A Levitzki, 1995, Science.

Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro.

A. Levitzki, A. Gazit, C. Gilon, 1996, Journal of medicinal chemistry.

Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.

G. Golomb, T. Sjöblom, A. Levitzki, 2003, Bioorganic & medicinal chemistry.

Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics*

A. Levitzki, A. Gazit, G. Blum, 2003, Journal of Biological Chemistry.

A. Levitzki, D. Leroith, A. Gazit, 2022 .

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

A. Levitzki, M. Freedman, A. Gazit, 1996, Nature.

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.

A. Levitzki, A. Gazit, C. Gilon, 1989, Journal of medicinal chemistry.

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

A. Levitzki, A. Gazit, C. Gilon, 1988, Science.

Benzologs of pentanona- and heptanona-fulvalenes☆

A. Gazit, M. Rabinovitz, 1972 .

Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.

A. Levitzki, A. Gazit, C. Gilon, 1991, Journal of medicinal chemistry.

Methyl vs. methylene condensation of aromatic aldehydes with 1,1,1-trifluoroacetylacetone

A. Gazit, Z. Rappoport, 1985 .

A [9] annulenone derivative

A. Gazit, M. Rabinovitz, E. Bergmann, 1971 .

4,5:8,9-DIBENZO-2,10-CYCLOUNDECADIEN-6-YNE: A POTENTIAL PRECURSOR OF A NON-BRIDGED [11]ANNULENYL CATION

A. Gazit, M. Rabinovitz, A. Dagan, 1975 .

A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.

V Hombach, V. Hombach, A. Levitzki, 1999, Circulation research.

Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by Staphylococcus aureus Cowan I.

G. Mills, A. Levitzki, A. Gazit, 1991, Journal of immunology.

Electrochemical redox properties of bridged and non‐bridged annulenediones

A. Gazit, J. Becker, 2022, Electrochemical Science Advances.

Flk-1 as a target for tumor growth inhibition.

A. Ullrich, G. Kéri, G. Mcmahon, 1996, Cancer research.

Inhibition of murine AIDS (MAIDS) development in C57BL/6J mice by tyrphostin AG-1387.

E. Sklan, A. Gazit, E. Priel, 2000, Virology.

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.

W. Cavenee, M. Nagane, H. Huang, 1998, Proceedings of the National Academy of Sciences of the United States of America.

T yr p ho s t in-I nd uced In hi bi t ion of p 2 1 Obcr-ab' Tyrosine Kinase Activity Induces K562 to Differentiate

A. Levitzki, Y. Ben-Neriah, A. Gazit, 2017 .

Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate.

A. Levitzki, Y. Ben-Neriah, A. Gazit, 1993, Blood.

Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.

E. Sausville, A. Levitzki, A. Gazit, 1994, Anti-cancer drugs.

Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells

Hua Yu, R. Jove, G. Niu, 2001, Oncogene.

The tryphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2.

A. Levitzki, A. Gazit, D. Ben‐Yehuda, 1997, Cancer research.

Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.

G. Mcmahon, P. Hirth, A. Levitzki, 1996, Bioorganic & medicinal chemistry.

Fluoro-clomiphene and its synthetic precursors: Synthesis and receptor binding

A. Gazit, T. Livshitz, Shani Jashovam, 1986, Steroids.

The pp60c‐Src inhibitor PP1 is non‐competitive against ATP

O. Livnah, A. Levitzki, A. Gazit, 2003, FEBS letters.

The potential of tyrphostins for the therapy of breast cancer.

A. Levitzki, A. Gazit, 2000, Breast disease.

Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells.

A. Zilberstein, A. Levitzki, A. Gazit, 1991, The American journal of physiology.

Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins.

A. Levitzki, D. Leroith, A. Gazit, 1997, Endocrinology.

Tyrphostin‐induced differentiation of mouse erythroleukemia cells

A. Levitzki, A. Gazit, C. Gilon, 1993, FEBS letters.

Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins.

A. Levitzki, A. Gazit, C. Gilon, 1993, The Journal of biological chemistry.

Oxidative stress protection by novel telomerase activators in mesenchymal stem cells derived from healthy and diseased individuals.

A. Gazit, A. Braiman, S. Slavin, 2013, Current molecular medicine.

DNA Topoisomerase I As One of the Cellular Targets of Certain Tyrphostin Derivatives

A. Gazit, E. Priel, Sarit Bendetz-Nezer, 2004 .

Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase.

A. Levitzki, A. Gazit, R. Capone, 1998, Experimental cell research.

Tyrphostins suppress the growth of psoriatic keratinocytes

A. Levitzki, A. Gazit, H. Ben-bassat, 1995, Experimental dermatology.

Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model.

I. Fishbein, G. Golomb, A. Levitzki, 1996, Atherosclerosis.

Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.

A. Levitzki, A. Gazit, R. Esteban, 1997, The Journal of clinical investigation.

Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors.

A. Levitzki, A. Gazit, N. Osherov, 1994, Science.

Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.

A. Levitzki, A. Gazit, M. Engel, 1994, Molecular pharmacology.

Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes.

A. Levitzki, A. Gazit, G. Plowman, 1997, Cancer research.

Nerve growth factor (NGF) promotes angiogenesis in the quail chorioallantoic membrane.

A. Gazit, P. Lazarovici, P. Lelkes, 2006, Endothelium : journal of endothelial cell research.

Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis.

C. Natanson, S. Banks, R. Danner, 1997, The Journal of clinical investigation.

The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

Teresa Guida, Alexander Levitzki, M. Santoro, 2002, Cancer research.

The Kinase Inhibitor PP 1 Blocks Tumorigenesis Induced by RET Oncogenes 1

M. Santoro, A. Fusco, A. Levitzki, 2002 .

Nucleophilic attacks on carbon-carbon double bonds. 33. Approaching the retention region from the stereoconvergence region in nucleophilic substitution of (E)- and (Z)-methyl p-substituted .alpha.-formyl- and .alpha.-(tert-butoxycarbonyl)-.beta.-halocinnamates

A. Gazit, Z. Rappoport, 1986 .

Nucleophilic attacks on carbon-carbon double bonds. 31. Complete and partial stereoconversion in vinylic substitution of (E)- and (Z)-.beta.-chloro-.alpha.-phenylcinnamaldehydes and (E)-2-iodo-1,2-diphenyl-1-nitroethylene by nucleophiles

A. Gazit, Z. Rappoport, 1985 .

PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine.

I. Fishbein, G. Golomb, L. Rabinovich, 1998, Circulation.

Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells.

Kuo‐Ting Chang, R. Perng, A. Levitzki, 1996, Cancer research.

Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats.

I. Fishbein, G. Golomb, L. Rabinovich, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase

R. Krais, A. Levitzki, N. Freedman, 2001 .

The effect of tyrphostin AG-556 on intimal thickening in a mouse model of arterial injury.

I. Barshack, A. Levitzki, A. Gazit, 2005, Experimental and molecular pathology.

Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.

R. Krais, A. Levitzki, N. Freedman, 2001, Nuclear medicine and biology.

Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries.

Alexander Levitzki, Ilia Fishbein, I. Fishbein, 2005, Biomaterials.

Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins.

A. Levitzki, A. Gazit, C. Gilon, 1993, Journal of medicinal chemistry.

Peptidomimetic tyrosine kinase inhibitors induce non apoptotic, Clarke-III type programmed cell death

G. Kéri, B. Szende, Z. Szegedi, 2002 .

Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins.

M. Bryckaert, A. Levitzki, A. Gazit, 1992, Experimental cell research.

Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins.

M. Bryckaert, A. Levitzki, A. Gazit, 1992, Experimental cell research.

Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins.

A. Gazit, D. Leroith, M. Párrizas, 1997, Endocrinology.

Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.

G. Mcmahon, P. Hirth, A. Levitzki, 1998, The Journal of pharmacology and experimental therapeutics.